Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the United States Securities and Exchange Commission on April 10, 2024. The report announces the termination of the consulting agreement with Dr. Bankole A. Johnson, who has served as the company's Chief Medical Officer. The agreement, which began on March 24, 2019, and was amended on March 22, 2022, and September 8, 2022, will be effectively terminated on May 17, 2024. Following this date, Dr. Johnson will no longer hold the position of Chief Medical Officer at Adial Pharmaceuticals. The company has fulfilled the SEC's requirements by having the report signed by President and Chief Executive Officer Cary J. Claiborne.

Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the United States Securities and Exchange Commission on April 10, 2024. The report announces the termination of the consulting agreement with Dr. Bankole A. Johnson, who has served as the company's Chief Medical Officer. The agreement, which began on March 24, 2019, and was amended on March 22, 2022, and September 8, 2022, will be effectively terminated on May 17, 2024. Following this date, Dr. Johnson will no longer hold the position of Chief Medical Officer at Adial Pharmaceuticals. The company has fulfilled the SEC's requirements by having the report signed by President and Chief Executive Officer Cary J. Claiborne.